logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Exelixis Has Good News Today and More is Expected

Exelixis and Bristol-Myers Squibb sNDA and sBLA Accepted by the FDA Exelixis ( EXEL ) and Bristol-Myers Squibb ( BMY ) announced that the United States FDA has accepted the supplemental Biologics License Application ( sBLA ) and supplemental New...

Read More

October 19, 2020

0

We Continue to Track the COVID-19 Vaccines. See Also: CRISPR Therapeutics Immuno-Oncology Results are Good.

The Latest on the COVID-19 Vaccines AstraZeneca ( AZN ): After pausing for more than a month, AZN is expected to resume its Phase 3 US study of its COVID-19 vaccine. The trial was paused after a patient, who received...

Read More

October 21, 2020

0

Gilead Sciences: Remdesivir is the First and Only Approved Treatment for Pediatric Patients with COVID-19. See Also: Cassava Sciences

Gilead Sciences Receives sNDA from the FDA for Remdesivir for Pediatric Patients with COVID-19 Gilead Sciences ( GILD ) announced that the U.S. Food and Drug Administration ( FDA ) has approved a supplemental new drug application ( sNDA )...

Read More

April 26, 2022

0

Amgen: Repatha Studies Showed Sustained Reduction in Low-Density Lipoprotein Cholesterol with No New Safety Findings

Amgen Repatha Studies Repatha is the Longest Studied PCSK9i Amgen ( AMGN ) announced top-line results from two Repatha® (evolocumab) open label extension ( OLE ) studies to the Phase 3 FOURIER cardiovascular outcomes trial. The studies were designed to assess...

Read More

April 27, 2022

0

Vertex Provided Successful Results of VX-880 for Type 1 Diabetes Then Placed the Product on Clinical Hold

A lot is happening while the Stock Market is tanking and is finally being considered a Bear Market. Trading in this Market as it is now is more like gambling rather than trading. We are working hard towards evaluating our...

Read More

May 2, 2022

0

Why We Expect a Lot from the Following Biotech Firms

Compugen Compugen ( CGEN ) announced the presentation of new research data that further support PVRIG as a potentially promising target for cancer immunotherapy. These data suggest that PVRIG inhibition may enhance T cell priming and infiltration into tumors and provide...

Read More

October 27, 2020

0

Karyopharm Therapeutics: CHMP Recommended Approval of the Firm's Product NEXPOVIO® for Multiple Melanoma in Europe.

Karyopharm Therapeutics  Karyopharm Therapeutics ( KPTI )  and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, announced that the European Medicines Agency's ( EMA ) Committee for Medicinal Products for Human Use ( CHMP ) has adopted a...

Read More

May 20, 2022

0

Rhythm Pharmaceuticals Achievements and Q3 Financial Results

Rhythm Pharmaceuticals Rhythm Pharmaceuticals ( RYTM ) reported financial results and provided a business update for the third quarter ended September 30, 2020. The firm develops treatments of rare genetic disorders of obesity. The FDA has accepted the firm's filed New...

Read More

November 2, 2020

0

Bausch + Lomb and Clearside Biomedical: FDA Approved XIPERE™ for Macular Edema Associated with Uveitis

Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ Bausch + Lomb, a leading global eye health business of  Bausch Health Companies ( BHC ),  and  Clearside Biomedical ( CLSD ) announced that the U.S. FDA approved XIPERE™...

Read More

October 25, 2021

0

What We Expect to Hear at the Regenxbio Conference Call Today

Regenxbio Conference Call Information Regenxbio will host a conference call today, at 4:30 pm est today, November 4, 2020, to discuss its financial results for the quarter, ended September 30, 2020, and recent operational highlights. To access the live call...

Read More

November 4, 2020

0

  • Previous
  • 1
  • 2
  • ...
  • 126
  • 127
  • 128
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy